Greg, a nice view to connect biotechs and high-techs.
===========================================================
netcognizance.com
Darren Mac, Gruntal
Author Lynn
Report Source Darren Mac
(Added 6/27/2000 9:13:29 AM)Categories: Market Views, Sector Reports, Stock Picks
Email link to this Article
Darren Mac, Gruntal: MLNM, AFFX, CALP, CRA, INCY
Says there is a close tie between biotech and hi-tech
Biotech is serving as the front-end discoverer of the pharm industry. As pharm companies need to maintain growth rates, they have to shift to enabling technologies to help them sort and makes sense of all the information coming out of the human genome project
The most abundant trend in biotech is the convergence between semiconductors and biology; AFFX is currently one of the leaders in this area
Example of this tech: If a researcher were to take a tissue sample from a patient cancer and then a patient without prostrate cancer, they could find out which genes were turned on and by knowing this, they can get a better idea which genes are implicated in the disease state
MLNM is another one of his picks: has to be in the best position to translate genome info into drug compounds
Has formed a platform that's the most productive and efficient and has been validated by over 1.8 billion in potential collaborative revs from pharm partners
CALP:
A very early emerging tech
Has great potential
"Lab on a chip" tech
Has modeled traditional lab procedures down to a microscale level allowing for decreased cost, decreased free agent usage, increased through put, eliminate human error, etc
CRA and INCY are probably the best known companies in providing computing information known as bioinformatics, still yet to be seen whether these business models will be profitable though
They face obsoleteness as they are facing the public human genome effort: why would a pharm company want to buy in to some of this data when they can wait a few months where they won't have to pay for it |
